CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1 enrolled
Drug / intervention
LILRB4 STAR-T cells injectionbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05739409
NCT05739409N/ACompleted
CompareCT.gov

An Exploratory Clinical Study on the Safety and Efficacy of LILRB4 STAR-T Cells in the Treatment of Monocytic Leukemia

Institute of Hematology & Blood Diseases Hospital, China·interventional·Posted Feb 22, 2023·Updated Feb 11, 2026

In Brief

A clinical study evaluating LILRB4 STAR-T cells injection for Acute Myelogenous Leukemia and Chronic Myelomonocytic Leukemia. Completed, enrolled 1 participant across 2 sites.

Detailed Summary

This is a single-center,single-arm,open-label phase I clinical study to determine the safety and efficacy of LILRB4 STAR-T cells in Monocytic Leukemia subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myelogenous Leukemia, Chronic Myelomonocytic Leukemia
CountriesChina
Collaborators--

Timeline

N/ACompletedFinished
202420252026
First PostedFeb 22, 2023
Enrollment StartFeb 16, 2023
Primary CompletionMay 9, 2023
TodayJul 1, 2026
Enrollment to primary: 3 monthsPosted 3.4 years ago

Interventions

LILRB4 STAR-T cells injectionbiological

The study population was relapsed/refractory acute myeloid leukemia and chronic myelomonocytic leukemia.Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4 and -3 followed by infusion of STAR-T cells. STAR-T cells will be intravenously infused with a escalated dose of 1E6#3E6#6E6#1E7 cells/kg